Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool April 21, 2008 Brian Lawler	Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear Rebuttal Generic competition for Lipitor is just the beginning. Faith is nice in terms of religion, but when it comes to investments, investors need to be able to make some reasonable assumptions about future growth plans.
The Motley Fool April 28, 2009 Brian Orelli	The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool July 24, 2008 Brian Lawler	Will Pfizer Pfizzle? The drugmaker posts strong earnings, but the good times may not last.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
The Motley Fool June 19, 2008 Brian Lawler	Pfizer's Small Lipitor Win Pfizer and the most prolific challenger of its Lipitor patents, Indian generic-drug manufacturer Ranbaxy, settle the vast majority of their litigation.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool July 18, 2007 Ryan Fuhrmann	Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note.
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
The Motley Fool June 1, 2007 Brian Lawler	The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool September 11, 2007 Brian Lawler	Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans.
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
The Motley Fool April 30, 2008 Brian Lawler	Pfizer Protects Profitable Patent The courts uphold a key patent on Pfizer's top drug.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool October 21, 2010 Brian Orelli	Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool April 20, 2004 Alyce Lomax	Pfizer's Fight First-quarter earnings give mixed messages on the drug maker's meds.
The Motley Fool October 19, 2009 Brian Orelli	Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease.
The Motley Fool September 30, 2008 Brian Orelli	Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool December 4, 2008 Brian Orelli	Pfizer Blows Statin Smoke Pfizer presents some mildly persuasive numbers to try to win back customers for Lipitor.
The Motley Fool July 30, 2009 Brian Orelli	A Little Help From the Enemy Unfortunately, it won't last. AstraZeneca went over a small patent cliff, but its competitors were nice enough to throw it some climbing gear.
The Motley Fool October 24, 2011	A Brief History of Pfizer's Returns At 14 times earnings, Pfizer looks reasonably valued, but not exactly cheap.
The Motley Fool June 27, 2005 Brian Gorman	Pfizer's Controversial Pairing The pharmaceutical's strategy of combining an experimental medicine with Lipitor will likely come under increasing fire. Investors, take note.
The Motley Fool April 21, 2004 Ben McClure	Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up?
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool October 30, 2009 Brian Orelli	World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth.
The Motley Fool January 24, 2008 Brian Lawler	Pfiltering Through Pfizer's Year Pfizer releases its 2007 numbers, displaying year-over-year earnings growth powered by foreign currency gains.
The Motley Fool October 21, 2004 Roger Nusbaum	Pictures of Lilly Eli Lilly's numbers get lost in the wake of Merck and Pfizer. While the market waits for drug stocks to recover, investors can collect Lilly's 2.5%, safe, dividend.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool August 16, 2011 Brian Orelli	Keeping Those Little Blue Pill Sales Up Pfizer wins a patent lawsuit for Viagra.
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.